Underactive Bladder: A Diary-First Workup Before Urodynamics

Underactive bladder is a contraction of reduced strength and/or duration that prolongs or fails to complete bladder emptying. It sits inside the Voiding-impairment "I" of the IPC 4Is framework alongside benign prostatic hyperplasia (BPH), with one critical difference: BPH is mechanical obstruction, underactive bladder is contractility failure. The two present similarly. The treatments diverge entirely. The diary, paired with a post-void residual scan, is what tells you which bucket the patient sits in before urodynamics confirms it.

A 71-year-old man with IPSS 18, weak stream, post-void dribbling, and persistent sense of incomplete emptying is started on tamsulosin 0.4 mg for presumed BPH. Six weeks in, no improvement. The reflexive next move is to escalate to combination therapy with a 5-alpha-reductase inhibitor and re-check at three months. The reflexive move is wrong. The diary, returned that visit, shows MVV of 170 mL, AVV of 120 mL, and three documented double-voids per day. PVR on POCUS reads 240 mL. This is not treatment-resistant BPH. This is underactive bladder, and adding 5-ARI will not move the contractility problem. The patient was misclassified at the front door, and the consequence is six months of failed pharmacology before anyone re-opens the differential.

This article walks the diary-first triage that flags underactive bladder before it enters the BPH treatment funnel. Most clinical writing on this topic stops at "you need urodynamics to distinguish UAB from BOO." That is true. It is also not enough, because the patient is six months into the wrong treatment by the time the urodynamics slot opens. The work the diary plus PVR plus a structured 4Is read does is upstream of urodynamics: it filters who needs it, who needs it urgently, and who needs different first-line management while the referral processes.

What underactive bladder is, and the terminology that confuses it

The International Continence Society defines detrusor underactivity (DU) as a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying or failure to achieve complete bladder emptying within a normal time span (Abrams et al., Neurourology and Urodynamics 2002; restated in Uren and Drake, Investigative and Clinical Urology 2017). DU is the urodynamic finding. Underactive bladder (UAB) is the symptom syndrome that suggests DU clinically but does not require urodynamic confirmation to name. The two terms are often used interchangeably in the literature; they are not the same construct, and the distinction matters for what counts as a confirmed diagnosis.

The historical labels for the same entity include hypotonic bladder, atonic bladder, lazy bladder, flaccid bladder, and detrusor hypoactivity. They all refer to the same physiology, with slight variation in how complete the contractility loss is. Modern terminology has converged on DU and UAB (Chapple et al., European Urology 2015). When you see "atonic bladder" in an older referral letter, read it as severe underactive bladder.

The term carries clinical weight because the syndrome is under-recognised. In urodynamic series of older adults with LUTS, detrusor underactivity is documented in 25 to 48% of elderly men and 12 to 24% of elderly women (Yu et al., Investigative and Clinical Urology 2017). The clinical implication of those numbers is that any clinician seeing more than a handful of older patients with weak-stream or refractory-LUTS presentations is encountering UAB regularly, often unrecognised.

Why the diagnosis gets missed

Two clinical patterns explain most missed diagnoses.

The alpha-blocker non-responder. A man over 60 presents with a weak stream and an IPSS in the moderate range. The reflexive presumed diagnosis is BPH. He is started on tamsulosin or alfuzosin. At the four-to-six-week recheck, symptoms are unchanged. The reflexive next move is to add a 5-alpha-reductase inhibitor or step up to combination therapy. The clinical entity getting missed is the contractility problem that an alpha-blocker cannot reach. A meaningful fraction of older men referred for refractory LUTS have detrusor underactivity rather than (or in addition to) bladder outlet obstruction, with urodynamic series documenting DU in 25 to 48% of elderly men with LUTS (Yu et al., Investigative and Clinical Urology 2017). When the alpha-blocker trial fails, contractility is the differential to chase, not dose escalation.

The "elderly weak stream is just BPH" reflex. Outside specialist urology, the assumption that male LUTS in an older patient is BPH by default is so reflexive that the differential rarely opens. Female UAB is missed even more often because the BPH framing does not anchor the workup, so the symptoms drift into "OAB" or "stress incontinence" buckets without any contractility check. UAB in women is prevalent and under-recognised; the symptom picture overlaps stress and urge presentations enough that the diagnosis is rarely made without a deliberate diary plus PVR check.

The third, less common pattern: the patient who has stopped reporting symptoms because they have adapted. They void by leaning forward, by abdominal straining, by visiting the bathroom every 90 minutes so the bladder never quite fills. The compensations work well enough that the patient stops complaining, and the chart entry stays "stable BPH" for years. The PVR scan is the only way to find this patient.

How underactive bladder differs from BPH (same I, different mechanism)

Both BPH and UAB live inside the Voiding-impairment "I" of the IPC 4Is framework. Same symptom domain, completely different mechanism. The symptom overlap is what makes them indistinguishable from the chair across the desk.

| Symptom | BPH (mechanical obstruction) | UAB (contractility failure) | |---|---|---| | Hesitancy | Yes | Yes | | Weak stream | Yes | Yes | | Straining | Often | Often | | Sensation of incomplete emptying | Often | Common | | Post-void dribbling | Common | Common | | Frequency / urgency (paradoxical) | Yes (rapid refill) | Yes (rapid refill) | | Overflow incontinence | Late | Late |

The diary, the uroflow, the PVR, and the urodynamic study are what differentiate them. Bladder outlet obstruction (BOO) produces a characteristic high-pressure, low-flow uroflow pattern, often with a plateau morphology. Detrusor underactivity produces a low-pressure, low-flow uroflow pattern, often with intermittency and dependence on abdominal straining to maintain flow. Pressure-flow urodynamics is the gold standard for the distinction. Pre-urodynamics, the closest non-invasive proxies are diary patterns plus uroflow shape plus PVR.

The clinical consequence of the mechanism difference is that BPH responds to outlet-directed therapy (alpha-blockers, 5-ARIs, surgical procedures that mechanically reduce obstruction). UAB does not. Surgical outcomes for BPH-directed procedures in patients with documented detrusor underactivity show worse short-term functional results than in patients with normal contractility, with IPSS and quality-of-life scores converging on longer follow-up (Wroclawski et al., Neurourology and Urodynamics 2024). The implication for the workup is straightforward: name the contractility status before committing to surgical management of the obstruction.

The diary patterns of underactive bladder

The 3-day bladder diary, read through the IPC 4Is, is the diagnostic substrate that flags UAB before urodynamics. The four diary signatures to look for:

1. Voiding efficiency below 70%. Voiding efficiency = voided volume / (voided + post-void residual). A patient who voids 200 mL but leaves 120 mL behind has a voiding efficiency of 62%. Repeated low efficiency across multiple voids on the diary is the single most specific UAB signal.
2. Low maximum voided volume (MVV). Often under 200 mL. Not because the bladder cannot hold more, but because the patient cannot empty enough to refill to functional capacity before the next urge. Pair this with normal capacity of the bladder to anchor what "normal" looks like for the comparison.
3. 24hVV often normal. No fluid imbalance driving the pattern. The total daily output sits in the 1.5 to 2.5 litre target range, which distinguishes UAB from a polyuria-driven frequency. Confirm with NPi calculation; UAB patients typically show NPi within age-appropriate range, separating them from the nocturnal polyuria population.
4. Double-void notation present. The patient documents 100+100 or 120+80 patterns within a single time slot, indicating they had to re-attempt voiding within minutes to clear retained urine. This is direct diary evidence of contractility failure.

A patient meeting three or more of these four signatures, with a PVR > 100 mL on POCUS at the follow-up visit, has a presumptive UAB diagnosis good enough to drive management decisions while the urodynamics referral processes. The bladder diary interpretation walkthrough carries the full read-through procedure.

The contrast with BOO diary patterns is subtle but real. BOO patients can have similar PVR and similar low MVV, but typically retain better voiding efficiency on the voids that complete (the obstruction is mechanical, not contractile, so when they push past it the void itself is often more complete). The diary's nuance is in the spread of voided volumes per void: UAB tends to produce small, scattered voids with high variance; BOO tends to produce small, consistent voids with low variance. This is a soft signal, not a hard rule.

Detrusor hyperactivity with impaired contractility (DHIC)

The patient with urgency, frequency, leakage, AND elevated PVR is not a treatment failure. They have detrusor hyperactivity with impaired contractility (DHIC), originally described by Resnick and Yalla in 1987 as a previously unrecognised but common cause of incontinence in older patients (Resnick and Yalla, JAMA 1987). DHIC presents with the storage-symptom cluster that flags as OAB on every standard questionnaire AND the elevated PVR that indicates Voiding-axis impairment. Both findings are real. The patient is not malingering and the test results are not contradictory.

The management implications of DHIC are different from pure OAB or pure UAB:

• Anticholinergics carry meaningfully larger retention risk in DHIC than in pure OAB. They can be used, but only with PVR monitoring at baseline and at 4 weeks; abandon if PVR climbs.
• Mirabegron is safer. Beta-3 agonists do not impair detrusor contractility and do not raise PVR meaningfully. Preferred first-line pharmacotherapy in DHIC.
• Behavioral therapy is first-line. Bladder retraining, fluid pacing, pelvic-floor coordination work led by a pelvic-floor PT. Often more effective than pharmacology in this profile.
• Pelvic-floor coordination matters. DHIC patients frequently have a coordinated-emptying problem at the floor that responds to PT-led work better than to medications.

DHIC is the diagnosis that gets called "treatment-resistant OAB" when the workup stops at the questionnaire. The PVR scan is what reframes it. The DHIC patients I find most worth catching early are not the ones who fail pharmacology - they are the ones whose questionnaire flags as classic OAB, whose PVR was never checked, and who get an antimuscarinic prescribed at the first visit. By the time they come back in retention four weeks later, the diagnosis has cost them a hospital trip the diary plus a 30-second POCUS scan would have prevented.

When (and why) to refer for urodynamics

Pressure-flow urodynamics remains the gold standard for separating BOO from UAB. The triggers for referral:

• Failed alpha-blocker trial in a male patient with persistent voiding-axis symptoms
• PVR > 150 mL on two separate measurements (or > 200 mL on one)
• Recurrent UTI in a patient without obvious bladder outlet obstruction
• Suspected DHIC where pharmacology decisions hinge on the contractility diagnosis
• Candidacy assessment for sacral neuromodulation in suspected UAB
• Female patient with voiding-axis symptoms refractory to a behavioral trial

Pre-refer the patient knowing whether you suspect UAB or BOO, so the urodynamicist asks the right questions and runs the right protocols. The referral note should specify which mechanism you are working to confirm or rule out, the diary findings that drive the suspicion, the PVR values across measurements, and any prior pharmacotherapy trials. A "rule out UAB" referral with the diary attached gets a different urodynamic study than a generic "evaluate LUTS."

The preserved-contractility versus acontractile distinction matters. Sacral neuromodulation (SNM) response rates in UAB are higher in patients who retain some baseline contractility: in a published staged-trial cohort, 57% of patients with preserved contractility responded to SNM compared with 33% of patients with detrusor acontractility (Chan et al., World Journal of Urology 2021). That distinction is determined at urodynamics and shapes how you frame the SNM conversation with the patient before referral to a centre offering it.

What to do (and not to do) while you wait for urodynamics

The wait between primary-care suspicion of UAB and a urodynamics slot routinely runs 4 to 12 weeks. The patient needs management in the meantime.

DO:

• Timed voiding at 60 to 90 minute intervals to prevent over-distention. Over-distention is itself a myogenic cause of UAB; the patient who has been suppressing the urge for hours at a time is making the contractility problem worse.
• Double-voiding teaching. Sit, void, wait 30 seconds, lean forward, void again. Often recovers an additional 40 to 80 mL per session.
• Fluid pacing. Small frequent sips instead of boluses. A 400 mL bolus over 15 minutes overwhelms the rate at which the kidneys can produce manageable output, which presents as urgency the impaired-contractility bladder cannot respond to.
• Constipation management. A full rectum mechanically impedes detrusor emptying. Bowel-tracking on the same diary, escalating fibre and fluid pacing first.
• POCUS-monitored re-checks. Repeat PVR at the next visit to confirm trend, not point estimate.

DON'T:

• Add an anticholinergic to a patient with PVR > 100 mL without monitoring PVR at week 4. Antimuscarinic-precipitated retention is a measurable outcome the workup should not be producing.
• Escalate the alpha-blocker dose without re-checking PVR. If the alpha-blocker is not working, dose-doubling rarely helps and can mask the underlying contractility problem.
• Blame the patient for "non-adherence" if they have stopped straining. Straining can worsen pelvic-floor coordination problems and can produce hemorrhoids, hernias, and prolapse over time. The patient who has stopped pushing is doing the safer thing.

Treatment options

Treatment for underactive bladder runs a ladder, and the rungs higher up have less evidence behind them than clinicians or patients typically realise. Set expectations early.

• Behavioral first. Timed voiding, double-voiding, fluid pacing, constipation management, pelvic-floor coordination work led by a pelvic-floor PT. The non-pharmacological floor of every UAB management plan.
• Intermittent self-catheterisation (ISC). The most effective long-term management option for moderate-to-severe UAB. Requires hand dexterity and intact cognition; teach by a continence nurse or pelvic-floor PT with experience in catheter education. Three-to-four ISC sessions per day in a typical pattern. Reduces UTI risk compared to indwelling catheters and preserves quality of life better in most patients.
• Indwelling catheter. When ISC is not feasible (cognitive impairment, dexterity loss, caregiver-availability constraints, frailty). Suprapubic (SPC) is generally more comfortable than urethral and easier for community nurses to change. Reserve for patients in whom ISC has been genuinely tried and not just gestured at.
• Sacral neuromodulation (SNM). The only proven contractility-modifying intervention. Response rates depend strongly on preserved-contractility status as established at urodynamics. Two-week trial protocol; coverage varies by region. Frame the conversation with the patient as "promising option for some, low-yield for others, the urodynamic study tells us which."
• Pharmacotherapy. Bethanechol historically; the recent systematic review concluded that the evidence base for parasympathomimetic treatment in UAB is too limited to support clear evidence-based recommendations, with future controlled trials needed (Moro et al., Neurourology and Urodynamics 2022). Mention without overselling. The pipeline includes detrusor-targeting agents in early clinical development; not yet ready for routine practice.
• Surgery. Prostatic surgery if BOO co-exists with UAB; outcomes are poorer than in BOO alone but can still help selected patients. Mitrofanoff and bladder augmentation procedures are rare and reserved for very specific indications.

The role of the pelvic-floor PT in UAB management is under-appreciated. Coordination work, breathing-pressure relationships, and posture-on-the-toilet adjustments often produce measurable PVR reduction in patients whose impairment is partly a pelvic-floor coordination problem rather than pure detrusor failure. PT-led behavioral management before or alongside any pharmacology trial is appropriate first-line management for most outpatient UAB presentations, not a downstream referral target.

ICD-10 coding

A quick reference because this is a search clinicians actually run:

• N31.2 Flaccid neuropathic bladder, not elsewhere classified
• N31.8 Other neuromuscular dysfunction of bladder
• N31.9 Neuromuscular dysfunction of bladder, unspecified
• R33.9 Retention of urine, unspecified (when DU is suspected but not yet confirmed)

Coding nuance varies by payer and by whether the underlying cause has been identified (diabetic, post-surgical, idiopathic). Document the contractility finding explicitly in the chart note when urodynamics confirms it.

FAQ

How do you fix an underactive bladder? There is no curative treatment for underactive bladder. Management focuses on ensuring complete bladder emptying through behavioral techniques (timed voiding, double-voiding), intermittent self-catheterisation, indwelling catheterisation when ISC is not feasible, and sacral neuromodulation in selected patients with preserved contractility. Pharmacotherapy has limited evidence. Pelvic-floor PT-led coordination work often produces measurable PVR improvement in patients with a coordination component to their impairment.

What are the symptoms of an underactive bladder? Hesitancy (waiting for the stream to start), slow or weak urinary stream, the need to strain or push to empty, prolonged voiding time, sensation of incomplete bladder emptying, post-void dribbling, the need to double-void within minutes of finishing, paradoxical urgency and frequency from rapid bladder refill, and in severe cases overflow incontinence (continuous dribbling from a chronically full bladder).

Does holding your pee strengthen your bladder? No, and this is one of the more dangerous misconceptions in bladder health. Chronic over-distention is itself a recognised myogenic cause of underactive bladder. Repeated holding past the point of normal urge stretches the detrusor, weakens it over time, and is one of the few self-inflicted contributors to UAB the patient can avoid. The advice "drink more water and hold it longer to train your bladder" is structurally backwards for any patient with voiding-axis symptoms.

What medication is used for underactive bladder? No medication has robust evidence for restoring detrusor contractility. Bethanechol has historical use but limited efficacy data and a side-effect profile (sweating, salivation, abdominal cramping, bradycardia) that often outweighs benefit. Distigmine is used in some jurisdictions outside the US. Pipeline detrusor-targeting agents are in early clinical development. The honest answer is that pharmacology is not the primary lever in UAB management; ensuring complete emptying through ISC, behavioral techniques, or SNM is.

Is underactive bladder serious? It can be. The complications of untreated UAB include recurrent UTI, bladder stones, vesicoureteral reflux that can damage the kidneys, and chronic urinary retention. Severity ranges from mild (occasional sense of incomplete emptying with PVR < 200 mL) to severe (frank chronic retention with PVR > 500 mL and risk of upper-tract injury). The seriousness depends on how complete the contractility loss is and whether emptying is being maintained by other means.

Can underactive bladder be cured? Generally no. Some reversible causes (a long-standing bladder outlet obstruction released surgically, certain medications stopped, a treated infection) can produce partial recovery. Most UAB is chronic and managed rather than cured. Sacral neuromodulation is the intervention with the most evidence for partial functional recovery, with response rates around 57% in patients with preserved contractility and 33% in patients with detrusor acontractility on baseline urodynamics.

What is the ICD-10 code for underactive bladder? The most commonly used codes are N31.8 (other neuromuscular dysfunction of bladder) and N31.9 (neuromuscular dysfunction of bladder, unspecified). N31.2 (flaccid neuropathic bladder) applies when the contractility loss is documented as neurogenic. R33.9 (retention of urine) applies in the workup phase before DU is formally confirmed.

Bringing this into your week

Pick one patient on your schedule next week with weak-stream presentation that has not improved on an alpha-blocker trial. Hand out a 3-day bladder diary with a 250 mL measuring cup. Schedule the follow-up for one week out, with a PVR scan at the start of that visit. At the visit, run the four-signature read on the diary (voiding efficiency, MVV, 24hVV, double-void notation) and overlay the PVR. If three or more signatures are present and the PVR is > 100 mL, you have a presumptive UAB diagnosis good enough to switch the management strategy from alpha-blocker dose escalation to a behavioral plus PT plus urodynamics referral plan.

The 71-year-old man in the opening case hit four of four signatures: MVV of 170 mL, low AVV, three documented double-voids per day, PVR of 240 mL, voiding efficiency calculable at 46% on the largest void. Tamsulosin came off. Timed voiding, double-void teaching, and a urodynamics referral went on the same visit. The differential opened the day the diary returned, not three months later when a 5-ARI trial would also have failed.

The discipline that takes longer to build than the workflow itself is the willingness to re-open a BPH diagnosis once it has been entered in the chart. That re-opening is the move the data is asking for. The diary is what gives you cover to make it.

Author: Dr. Di Wu, MD, PT (IPC founding member). Medically reviewed by Dr. Steven Tijerina, PT, DPT, Cert. MDT (IPC US Director). Photo: Laura Ockel on Unsplash.